FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980287658> ?p ?o ?g. }

• W2980287658 endingPage "2190" @default.
• W2980287658 startingPage "2190" @default.
• W2980287658 abstract "Abstract Most CML patients are sensitive to Imatinib Mesylate (IM), however, a small fraction develop resistance, mostly through the onset of BCR-ABL mutations. More than 30 mutations have been described, mostly in advanced phase, and confer different levels of clinical resistance. In this setting, clinical trials with 2nd generation tyrosine kinase inhibitors (TKI) provide encouraging results, however neither in vitro nor clinical activity has been demonstrated when the most frequent BCR-ABL mutation, T315I, has been identified. In this retrospective study from 5 French centers, we analysed the features and clinical outcomes of 27 CML patients treated with IM and presenting either clinical, cytological, cytogenetic resistance or molecular progression, and harboring a BCR-ABLT315I mutation detected by direct sequencing (same method in the 5 different laboratories, quality control exchanges). The 27 patients were in chronic phase (CP) at diagnosis, with 17 M and 10 F with a median age at diagnosis of 52 (25–70). Sokal scores were high for 8 pts, intermediate for 6 pts, low for 3 pts and unknown for 8, 2 were in blast crisis (BC) at CML diagnosis. Transcripts were M-BCR for 22 patients and m-BCR for 2 patients and unknown for 3 pts. At diagnosis 4 pts had additional chromosomal abnormalities as a variant Ph1 chromosome, a -7, a -Y, and an additional t(3;7;12) to the Ph1. Progression has been defined as a 2-fold rise in BCR-ABL transcripts levels, loss of any previous response to IM, and a transition towards a more advanced phase of the disease. At T315I discovery, 11 pts were in CP, 4 in accelerated phase, and a majority in BC [7 in myeloid and 5 in lymphoid]. The median interval between diagnosis and IM was 20 Mo. (0–145.2). The median initial dose of IM was 464 mg/day. Most of the patients were poor responders to IM of which 12 pts that obtained no more than a CHR, 2 pts a PCyR, 7 pts a CcyR, 2 pts a MMR, 1 pt no response, and 3 unknown. Twenty-one pts harboured a T315I alone, 1 a T315I with a Y253H, 2 with a M351T, 1 with a E255K+E255V, 1 with a L324Q, and 1 with a F311L, with no impact on survival. The median time for progression from day 1 IM was short [13 Mo. (0–49.6)] regardless of the phase of the disease at T315I identification, and the median interval IM start-T315I identification was 20 Mo. (0–57.6). Median overall survival from D1 of IM was 17.5 Mo. for advanced phases and 42.5 Mo. for CP (p=0.08). All patients progressed with no difference for time to progression between phases (p>0.05). Figure Figure Neither additional mutations (p=0.91), nor additional chromosomal abnormalities (p=0.11), nor Dasatinib treatment (p=0.15) modified overall survival. In conclusion, the onset of BCR-ABLT315I mutations occurs preferentially in high-risk CML, seems more frequent in advanced phases, and is always responsible for progression and poor survival, underlying the need for alternative treatments, in patients lacking a histocompatible donor." @default.
• W2980287658 created "2019-10-18" @default.
• W2980287658 creator A5008609620 @default.
• W2980287658 creator A5018416096 @default.
• W2980287658 creator A5029315909 @default.
• W2980287658 creator A5040576970 @default.
• W2980287658 creator A5045283637 @default.
• W2980287658 creator A5045894818 @default.
• W2980287658 creator A5053019069 @default.
• W2980287658 creator A5055166871 @default.
• W2980287658 creator A5067191211 @default.
• W2980287658 creator A5068342352 @default.
• W2980287658 creator A5072027146 @default.
• W2980287658 creator A5075748175 @default.
• W2980287658 creator A5075844368 @default.
• W2980287658 creator A5077014294 @default.
• W2980287658 creator A5084671985 @default.
• W2980287658 creator A5087870886 @default.
• W2980287658 date "2006-11-01" @default.
• W2980287658 modified "2023-10-14" @default.
• W2980287658 title "Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation." @default.
• W2980287658 doi "https://doi.org/10.1182/blood.v108.11.2190.2190" @default.
• W2980287658 hasPublicationYear "2006" @default.
• W2980287658 type Work @default.
• W2980287658 sameAs 2980287658 @default.
• W2980287658 citedByCount "0" @default.
• W2980287658 crossrefType "journal-article" @default.
• W2980287658 hasAuthorship W2980287658A5008609620 @default.
• W2980287658 hasAuthorship W2980287658A5018416096 @default.
• W2980287658 hasAuthorship W2980287658A5029315909 @default.
• W2980287658 hasAuthorship W2980287658A5040576970 @default.
• W2980287658 hasAuthorship W2980287658A5045283637 @default.
• W2980287658 hasAuthorship W2980287658A5045894818 @default.
• W2980287658 hasAuthorship W2980287658A5053019069 @default.
• W2980287658 hasAuthorship W2980287658A5055166871 @default.
• W2980287658 hasAuthorship W2980287658A5067191211 @default.
• W2980287658 hasAuthorship W2980287658A5068342352 @default.
• W2980287658 hasAuthorship W2980287658A5072027146 @default.
• W2980287658 hasAuthorship W2980287658A5075748175 @default.
• W2980287658 hasAuthorship W2980287658A5075844368 @default.
• W2980287658 hasAuthorship W2980287658A5077014294 @default.
• W2980287658 hasAuthorship W2980287658A5084671985 @default.
• W2980287658 hasAuthorship W2980287658A5087870886 @default.
• W2980287658 hasConcept C104317684 @default.
• W2980287658 hasConcept C126322002 @default.
• W2980287658 hasConcept C138626823 @default.
• W2980287658 hasConcept C143998085 @default.
• W2980287658 hasConcept C170493617 @default.
• W2980287658 hasConcept C2776960273 @default.
• W2980287658 hasConcept C2777583451 @default.
• W2980287658 hasConcept C2778461978 @default.
• W2980287658 hasConcept C2778729363 @default.
• W2980287658 hasConcept C2778904597 @default.
• W2980287658 hasConcept C3019892230 @default.
• W2980287658 hasConcept C43907098 @default.
• W2980287658 hasConcept C501734568 @default.
• W2980287658 hasConcept C502942594 @default.
• W2980287658 hasConcept C535046627 @default.
• W2980287658 hasConcept C54355233 @default.
• W2980287658 hasConcept C71924100 @default.
• W2980287658 hasConcept C86803240 @default.
• W2980287658 hasConceptScore W2980287658C104317684 @default.
• W2980287658 hasConceptScore W2980287658C126322002 @default.
• W2980287658 hasConceptScore W2980287658C138626823 @default.
• W2980287658 hasConceptScore W2980287658C143998085 @default.
• W2980287658 hasConceptScore W2980287658C170493617 @default.
• W2980287658 hasConceptScore W2980287658C2776960273 @default.
• W2980287658 hasConceptScore W2980287658C2777583451 @default.
• W2980287658 hasConceptScore W2980287658C2778461978 @default.
• W2980287658 hasConceptScore W2980287658C2778729363 @default.
• W2980287658 hasConceptScore W2980287658C2778904597 @default.
• W2980287658 hasConceptScore W2980287658C3019892230 @default.
• W2980287658 hasConceptScore W2980287658C43907098 @default.
• W2980287658 hasConceptScore W2980287658C501734568 @default.
• W2980287658 hasConceptScore W2980287658C502942594 @default.
• W2980287658 hasConceptScore W2980287658C535046627 @default.
• W2980287658 hasConceptScore W2980287658C54355233 @default.
• W2980287658 hasConceptScore W2980287658C71924100 @default.
• W2980287658 hasConceptScore W2980287658C86803240 @default.
• W2980287658 hasIssue "11" @default.
• W2980287658 hasLocation W29802876581 @default.
• W2980287658 hasOpenAccess W2980287658 @default.
• W2980287658 hasPrimaryLocation W29802876581 @default.
• W2980287658 hasRelatedWork W14061706 @default.
• W2980287658 hasRelatedWork W1519449155 @default.
• W2980287658 hasRelatedWork W1921338684 @default.
• W2980287658 hasRelatedWork W2083207258 @default.
• W2980287658 hasRelatedWork W2147270774 @default.
• W2980287658 hasRelatedWork W2149357045 @default.
• W2980287658 hasRelatedWork W2158460758 @default.
• W2980287658 hasRelatedWork W2323167910 @default.
• W2980287658 hasRelatedWork W2552820660 @default.
• W2980287658 hasRelatedWork W2979508620 @default.
• W2980287658 hasVolume "108" @default.
• W2980287658 isParatext "false" @default.
• W2980287658 isRetracted "false" @default.
• W2980287658 magId "2980287658" @default.
• W2980287658 workType "article" @default.